Monday, December 19, 2011

Ranbaxy gains traction in atorvastatin generics - Gains 14% market share

It seems Ranbaxy to gain market share, is offering a higher price discount than the traditional 40% -50%.  Atorvastatin will continue to be a low competition window, even post expiry of exclusivity, which should help Ranbaxy make the most out of atorvastatin generics. 
In 2012, other exclusivities for Ranbaxy include Diovan, Actos, Provigil. Besides these exclusivities, it is also anticipated that they might get the Nexium supply contract from AZN.

No comments:

Post a Comment